• Explore /
  • Poster
  • / LANTana trial protocol: An open label, single arm, phase Ib study to evaluate the effect of pre-treatment with ASTX727 (a demethylating agent) followed by lutetium Lu 177 dotatate in patients with progressive, metastatic neuroendocrine neoplasias (NENs).

LANTana trial protocol: An open label, single arm, phase Ib study to evaluate the effect of pre-treatment with ASTX727 (a demethylating agent) followed by lutetium Lu 177 dotatate in patients with progressive, metastatic neuroendocrine neoplasias (NENs).

Abstract Poster

Authors

null

Rohini Sharma

Imperial College London, London, United Kingdom

Rohini Sharma , Caroline Ward , Mitesh Naik , Saraih Khan , Tara Barwick , Maria Martinez , Hooshang Izadi , Eric O. Aboagye

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT05178693

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4192)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4192

Abstract #

TPS4192

Poster Bd #

502b

Abstract Disclosures

Similar Posters

First Author: Aman Chauhan

First Author: Timothy Jay Price

First Author: Estephany Abou Jokh Casas

First Author: Alexander Rheinhard Siebenhuener